FIGURE 2.
Information component and its 95% credibility interval over time for different types of anti-VEGF-associated ocular adverse events. Abbreviations: ●, Ranibizumab; ■, Aflibercept; ▲, Brolucizumab; IC, information component; CI, credibility interval. The error bars show the 95% credibility interval (CI) of the information component (IC), when the IC curve is steady upward trend and the 95% CI narrowed, the signal is stable and strong association.